Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;26(4):953-960.
doi: 10.1007/s10741-020-09925-z.

Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future

Melanie Nana  1 , Holly Morgan  2 , L N Rao Bondugulapati  3
Affiliations
Review

Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future

Melanie Nana et al. Heart Fail Rev. 2021 Jul.

Abstract

Type 2 diabetes mellitus is associated with an increased risk of heart failure. The prevalence of type 2 diabetes mellitus is on an upward trend. Heart failure represents one of the major causes for hospitalisation and mortality despite advances in management. Recent cardiovascular outcome trials have demonstrated that sodium-glucose co-transporter 2 inhibitors, which were introduced to the market in 2013, can incur a clinically significant risk reduction in heart failure outcomes in such patients. In this review, we discuss the epidemiology and pathophysiology of heart failure in diabetes and explore the landmark trials, the potential mechanisms of benefit of SGLT-2 inhibitors in heart failure, how the trials have led to major changes in treatment guidelines, and future potential directions for use of these drugs, including in those without diabetes.

Keywords: Cardiovascular outcomes; Heart failure; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Rosano GM, Vitale C, Seferovic P (2017) Heart failure in patients with diabetes mellitus. Card Fail Rev 3(1):52–55 - PubMed - PMC
    1. von Bibra H, St John Sutton M (2010) Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia. 53(6):1033–1045
    1. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray J, CHARM Investigators (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29(11):1377–1385 - PubMed
    1. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care 40(5):671–678 - PubMed
    1. Lawson CA, Jones PW, Teece L, Dunbar SB, Seferovic PM, Khunti K, Mamas M, Kadam UT (2018) Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail 6(1):18–26 - PubMed

MeSH terms

LinkOut - more resources